Skip to content
PeptideBiz Guide

Sample · foundation draft excerpt

A short read from the guide

Two short excerpts. The full edition is not available yet.

Contents

  1. 1. The market in one page
  2. 2. Peptide science without the noise
  3. 3. The four lanes
  4. 4. The 2026 regulatory reset
  5. 5. 503A, 503B and GLP-1
  6. 6. RUO: what it is and is not
  7. 7. Human research, IRBs and PepMD
  8. 8. Manufacturing, API and supplier diligence
  9. 9. Quality, COAs and testing
  10. 10. Lyophilization, formulation and logistics
  11. 11. The healthcare delivery stack
  12. 12. Diagnostics, telehealth and pharmacy
  13. 13. Marketing and claims
  14. 14. Business models and economics
  15. 15. The 90-day launch framework
  16. 16. Where the industry is headed
  17. 17. Decision checklists
  18. 18. Sources and further reading

§9 Quality, COAs and testing

Quality is a chain of evidence

Quality is a chain of evidence connecting purchase order, lot number, manufacturing record, sample, test method, laboratory result, release decision, storage condition and shipment.

A certificate of analysis is one link in that chain. Read on its own, it cannot show that the tested sample matches the shipped lot.

§15 The 90-day launch framework

Days 1–15: classify first

Days 1–15 — classify: customer, product, intended use, entity roles, state footprint, claims and regulatory questions. Create a launch-readiness register with owner, evidence and status.

SAMPLE — Peptide Biz Guide. Editorial education only; not medical, legal or regulatory advice.